y studies have shown that the degree of matrix metalloproteinase (particularly MMP9) increases right after stroke, and is linked with BBB disruption (Turner and Sharp, 2016). A clinical study showed that the improved serum MMP9 level in acute phase of IS was related with 3-months cognitive impairment (Zhong et al., 2018). Selective inhibition of gelatinase could be made use of to treat IS. Administration of MMPs inhibitors (BB-94) prior to rtPA therapy decreased mortality, suggesting that blocking MMPs activity reduces the danger associated with thrombolysis (Pfefferkorn and Rosenberg, 2003). In the acute phase of IS, IL1B and TNF promote inflammatory injury and induce cell necrosis or apoptosis (Bi et al., 2015). Reduction of serum IL1B ultimately enhance the clinical outcome of sufferers with IS (Kadri et al., 2020). Aprevious study showed that PTGS2 (also called cyclooxygenase-2) developed CDK3 manufacturer prostaglandins and thromboxanes, that are significant mediators of IS-induced inflammatory cascade (Dong et al., 2019). Protein expression of PTGS2 enhanced significantly following IS. The particular knockdown of PTGS2 can GSK-3α custom synthesis inhibit NF-B signaling pathway, thus inhibit apoptosis, market the proliferation, migration and angiogenesis of endothelial progenitor cells, and guard ischemic stroke mice (Zhou et al., 2019). In addition, the inflammatory response right after IS can also lead to neuron apoptosis, forming a vicious circle, which in turn aggravates the inflammatory response (Mergenthaler et al., 2004). General, our findings indicate that CR can act on the above inflammatory response related core targets within the therapy of IS.CONCLUSIONSThis study provides a preliminary exploration from the therapeutic impact of CR on ischemic brain injuries and its doable phytochemicals, and coniferyl ferulate, neocnidilide and ferulic acid are identified the important phytochemicals of CR against IS. Its brain protective effects involve anti-inflammation, anti-oxidant, anti-cell death and improving blood circulation. Simultaneously, stopping infection and regulating blood pressure would be the two essential manifestations with the synergistic effects of CR in treating IS. However, subsequent in vivo (oxygen-glucose deprivation model) and in vitro experiments have to be further proved. Additionally, toxicity and safety studies should be performed just before clinical translation. In summary, this study offers a pathophysiologically relevant pharmacological basis for further analysis on IS.Information AVAILABILITY STATEMENTThe raw information supporting the conclusions of this article will likely be produced offered by the authors, devoid of undue reservation.ETHICS STATEMENTThe animal study was reviewed and approved by The Animal Care and Use Committee of Huazhong University of Science and Technology.AUTHOR CONTRIBUTIONSPZ conceived this analysis. PZ and H-FS contributed towards the acquisition, analysis, and interpretation of data. C-YY and Y-WS helped inside the information acquisition. PZ drafted this manuscript. YY performed the animal experiment. X-WZ and YL gave significant ideas on the writing and revised the draft. AS and QT contributed to the data analysis strategy and improving the high quality of this paper. All authors agree to become accountable for all aspects of work making certain integrity and accuracy.Frontiers in Pharmacology | frontiersin.orgDecember 2021 | Volume 12 | ArticleZeng et al.Chuanxiong Rhizoma Against Ischemic StrokeFUNDINGThis work was supported by the grants from the National Natural Science Foundation of China (8204